Clinical trials proved intravitreal vascular endothelial growth factor inhibitors (anti-VEGF agents) to be able to stabilise or even improve visual acuity outcomes in various types of choroidal neovascularization. The purpose of the study is to identify prognostic factors and number of injections needed to obtain high visual acuity (equal or better than LogMAR 0.10) in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF agents.
Department of Ophthalmology, General Hospital of Lamia, Lamia, Greece
retrospective chart review of medical records of 85 patients with nAMD treated with anti-VEGF agents in General Hospital of Lamia. 42 elsewhere treatment-naïve patients (42 eyes) with more than one year follow up were identified. Age, gender, pseudophakia, baseline visual acuity, subretinal or intraretinal fluid at baseline, being the second eye affected, number of injections needed to achieve the best vision and achievement of visual acuity (VA) logMAR 0.10 or better were recorded. Fundus auto fluorescence imaging (FAF) was performed in 20/42 patients. Data were analysed with aparametric methods (Fischer’ s exact test and Wilcoxon-Mann-Whitney test)).
baseline VA 0.30 logMAR or better was identified as the only prognostic factor for the achievement of VA logMAR 0.10 or better (p=0.001). The best VA was achieved with 2 to 7 injections (median 3). All patients with VA=0.10 logMAR or better who were tested with FAF (6/12) showed minimal or no pathology.
patients at risk for nAMD should be followed up closely in order to diagnose the disease at the earliest possible stage and thus gain superior results with antiVEGF treatment. All available technology should be dedicated in this purpose.
no financial relation with any company
Secretariat Address European Society of Retina Specialists Ground Floor, The Apex Building Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2